CHICAGO — In a cohort of patients with difficult-to-control type 2 diabetes, approximately one-quarter had hypercortisolism, according to interim results of part 1 of the CAPTAIN-T2D study presented at ENDO 2026. The results are consistent with those of part 1 of the CATALYST trial, in which, as Healio previously reported, 23.8% of patients with difficult-to-control type 2 diabetes had